OPRX-106
PB-106-003
Phase 2 small_molecule active
Quick answer
OPRX-106 for Ulcerative Colitis is a Phase 2 program (small_molecule) at Protalix BioTherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Protalix BioTherapeutics
- Indication
- Ulcerative Colitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active